Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHARMA > CELL WALL SYNTHESIS INHIBITORS > Flashcards

CELL WALL SYNTHESIS INHIBITORS Flashcards

1
Q

T/F

→ bacterial cell wall composition:
o peptidoglycan
o glycan units joined by peptide cross-linkages

→ to be maximally effective, these inhibitors require actively proliferating microorganisms

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

among the widely effective antibiotic and least toxic drug

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

→ increased resistance has limited its use

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

members of this group differ in the R substituent attached to 6-aminopenicillanic acid residue

o nature of this side chain affects the antimicrobial spectrum,
stability to gastric acid and susceptibility to bacterial degradative enzymes (B-Lactamase)

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

interfere with bacterial cell wall synthesis (transpeptidation or cross-linkage)

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

cell lysis or cell death

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

T/ F

cell lysis through osmotic pressure or activation of autolysins

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

cell lysis or cell death is related to:

A

o antibiotic size
o charge
o hydrophobicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

effective only against rapidly growing organisms or those that synthesize peptidoglycan cell wall

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

not effective in microorganisms devoid of peptidoglycan cell wall

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

T/F

ANTIBACTERIAL SPECTRUM
is determined by the ability to cross bacterial peptidoglycan cell wall and to reach PBP in periplasmic space

A

T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

possess a cell wall easily traversed by penicillin
→ susceptible

A. Gram (+) Bacteria
B. Gram (-) Bacteria

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Thicker cell wall

A. Gram (+) Bacteria
B. Gram (-) Bacteria

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Can resist antibiotic

A. Gram (+) Bacteria
B. Gram (-) Bacteria

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

possess outer lipopolysaccharide membrane that serves as a barrier to water-soluble penicillin

A. Gram (+) Bacteria
B. Gram (-) Bacteria

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

may also posses proteins inserted along the lipopolysaccharide layer that act as water-channels, “porins”
to permit transmembrane entry

A. Gram (+) Bacteria
B. Gram (-) Bacteria

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

exception:
o Pseudomonas lacks porins
making it resistant to many antimicrobials

A. Gram (+) Bacteria
B. Gram (-) Bacteria

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

obtained from fermentation of mold Penicillium chrysogenum

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

PENICILLIN G (BENZYL-PENICILLIN)

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

cornerstone in treatment for infection of gram (+) & (-) cocci, (gram (+) bacilli, and spirochetes

A. PENICILLIN G (BENZYL-PENICILLIN)
B. PENICILLIN V

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

can be inactivated by B-Lactamase (PCNases)

A. PENICILLIN G (BENZYL-PENICILLIN)
B. PENICILLIN V

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

not used in treatment of bacteremia because it needs higher
minimum concentration to eliminate infection

A. PENICILLIN G (BENZYL-PENICILLIN)
B. PENICILLIN V

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

more acid-stable; administered orally

A. PENICILLIN G (BENZYL-PENICILLIN)
B. PENICILLIN V

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

effective against some anaerobic organisms

A. PENICILLIN G (BENZYL-PENICILLIN)
B. PENICILLIN V

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

B-Lactamase (PCNase) resistant

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

used in treatment of infections caused by PCNase producing
staphylococci

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Methicillin is not used clinically due to toxicity and is only used
to identify resistant strains of Staph. aureus (MRSA)

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Ampicillin and Amoxicillin

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

→ have similar antibacterial spectrum with PCN-G
→ more effective against gram (-) bacilli

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

→ drug of choice for gram (+) bacillus L. monocytogenes
→ used in treatment of respiratory infection

A. AMPICILLIN
B. AMOXICILLIN

A

A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

used by dentists for prophylaxis in patients with heart valve disease to undergo extensive oral surgery

A. AMPICILLIN
B. AMOXICILLIN

A

B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Piperacillin is the most potent

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

effective against many gram (-) bacilli but not Klebsiella (due to
PCNase)

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Clavulanic Acid + Ticarcillin

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Tazobactam + Piperacillin

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

have a synergistic relationship because cell wall inhibitors alter the permeability of bacterial cells which facilitate entry of other antibiotics to intracellular target sites → enhanced antimicrobial activity

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

combination of both is used clinically but should never be in one infusion fluid

o aminoglycoside is positively charged while PCN is negatively charged

A. NATURAL PENICILLIN
B. ANTISTAPHYLOCOCCAL PENICILLIN
C. EXTENDED SPECTRUM PENICILLIN
D. ANTIPSEUDOMONAL PENICILLINS
E. PENICILLIN & AMINOGLYCOSIDES

A

E

38
Q

→ lacks peptidoglycan cell wall

A. Natural Resistance
B. Acquired Resistance

A

A

39
Q

cell wall that is impermeable to PCN

A. Natural Resistance
B. Acquired Resistance

A

A

40
Q

through plasmid transfer which encodes resistance

A. Natural Resistance
B. Acquired Resistance

A

B

41
Q

PROPERTIES OF PLASMID-RESISTANCE BACTERIA
[3]

A

BETA-LACTAMASE ACTIVITY

DECREASED PERMEABILITY OF OUTER MEMBRANE TO THE ANTIBIOTIC

ALTERED PBPs

42
Q

these enzymes hydrolyze cyclic amide bond of B-Lactam ring which results in loss of bactericidal activity

A. BETA-LACTAMASE ACTIVITY
B. DECREASED PERMEABILITY OF OUTER MEMBRANE TO THE ANTIBIOTIC
C. ALTERED PBPs

A

A

43
Q

either naturally occurring or acquired by the transfer of plasmids

A. BETA-LACTAMASE ACTIVITY
B. DECREASED PERMEABILITY OF OUTER MEMBRANE TO THE ANTIBIOTIC
C. ALTERED PBPs

A

A

44
Q

prevents it from reaching target protein PBP

A. BETA-LACTAMASE ACTIVITY
B. DECREASED PERMEABILITY OF OUTER MEMBRANE TO THE ANTIBIOTIC
C. ALTERED PBPs

A

B

45
Q

have a lower affinity for B-Lactam antibiotics and will need unattainable concentration of antibiotic to take effect (MRSA)

A. BETA-LACTAMASE ACTIVITY
B. DECREASED PERMEABILITY OF OUTER MEMBRANE TO THE ANTIBIOTIC
C. ALTERED PBPs

A

C

46
Q

secretes B-Lactamase extracellularly

A. Gram (+) Bacteria
B. Gram (-) Bacteria

A

A

47
Q

confine B-Lactamase within periplasmic space

A. Gram (+) Bacteria
B. Gram (-) Bacteria

A

B

48
Q

T/ f

IV or IM for all antipseudomonal PCN (Ticarcillin, Carbenicillin, Piperacillin)

A

T

49
Q

T/ f

Oral for Pen V; Amoxicillin

A

T

50
Q

T/ F

Procaine Pen-G and Benzathine Pen-G given IM

A

T

51
Q

T/ F

ABSORPTION

Amoxicillin is almost completely absorbed; not appropriate for treatment of Shigella or Salmonella-derived enteritis (does not reach intestinal crypts)

A

T

52
Q

T/F

Absorption

Amoxicillin is almost completely absorbed; not appropriate for treatment of Shigella or Salmonella-derived enteritis (does not reach intestinal crypts)

A

T

53
Q

T/ F

DISTRIBUTION

all penicillin cross placental barrier and are non-teratogenic

A

T

54
Q

T/ F

Penicillin is excreted through kidney or breast milk

A

T

55
Q

T/ f

PENICILLIN
Adverse reactions:

Hypersensitivity [maculopapular rash, angioedema, anaphylaxis]

A

T

56
Q

T/ f

PENICILLIN
Adverse reactions:

Diarrhea, Nephritis, Neurotoxicity, Hematologic Toxicities

A

T

57
Q

decreased coagulation caused by anti-pseudomonal penicillin and Pen-G; eosinophilia

A

Hematologic Toxicities

58
Q

are B-Lactam antibiotics that are closely related as to structure and function to penicillin

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

B

59
Q

→ most are produced semi-synthetically
→ same mode of action with penicillin and are affected by the same resistance mechanism but tend to be more resistant to certain B-Lactamases

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

B

60
Q

classified as first, second, third, or fourth generation based on their susceptibility patterns and resistance to B-Lactamases

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

B

61
Q

ineffective against MRSA, L. monocytogenes, Clostridium difficile, and Enterococci

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

B

62
Q

act as Pen-G substitute; resistant to staph penicillinase

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

A

63
Q

has activity against P. mirabilis, E. coli, K. pneumoniae

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

A

64
Q

have greater activity against gram (-) organisms (ex.: H. influenza, Enterobacter aerogenes, Neisseria species)

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

B

65
Q

have a weaker action on gram (+) microorganisms

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

B

66
Q

have greater activity against gram (-) bacilli and most enteric organisms plus Serratia marcescens

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

C

67
Q

Ceftriaxone or Cefotaxime is the drug of choice for meningitis

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

C

68
Q

Ceftazidime has activity against P. aeruginosa

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

C

69
Q

Cefepime

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

D

70
Q

administered parenterally

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

D

71
Q

has a wide antibacterial spectrum of
activity; active against streptococci and
staphylococci

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

D

72
Q

effective against aerobic gram (-)
organisms (ex.: K. pneumoniae, Enterobacter, P. mirabilis, E. coli, P. aeruginosa)

A. First Generation
B. Second Generation
C. Third Generation
D. Fourth Generation

A

D

73
Q

RESISTANCE
→ same as with penicillin but not susceptible to hydrolysis by Staph penicillinase
→ susceptible to extended-spectrum B-Lactamase

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

B

74
Q

→ administered through IV or IM
→ poor oral absorption except for certain drugs (refer to summary
table)
→ all are well-distributed in body fluids
→ in the CSF, adequate therapeutic levels are achieved with third
generation regardless of inflammation
o Ceftriaxone or Cefotaxime are effective in treatment of
neonatal or childhood meningitis

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

B

75
Q

Cefazolin is used as a single-dose prophylaxis prior to surgery due to its 1.8 hours half-life and is effective against PCNase producing S. aureus
o also useful in orthopedic surgery because it can penetrate
bone
o all cephalosporins can cross the placenta

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

B

76
Q

T/F

allergic manifestations
o if allergic to penicillin, avoid cephalosporins

A

T

77
Q

mechanism of action:
o hydrolysis of B-Lactam ring by enzymatic cleave with
B-Lactamase or by an acid

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

C

78
Q

Clavulanic Acid, Sulbactam, Tazobactam
o contain B-Lactam ring
o bind to and inactivate B-Lactamases
o protect the antibiotic that are the normal substrates for
enzymes

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

C

79
Q

→ by themselves, do not have significant antibacterial activity
→ must be used in combination with B-Lactamase sensitive
antibiotic (ex.: Clavulanic Acid + Amoxicillin = for B-Lactamase producing E. coli)

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

C

80
Q

→ tricyclic glycopeptide
→ effective against multiple drug resistant microorganisms
→ MRSA and enterococci

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

D

81
Q

MODE OF ACTION
→ inhibit synthesis of bacterial cell wall phospholipids and peptide-glycan polymerization; thus, weaken cell wall and damage underlying cell membrane

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

D

82
Q

ANTIBACTERIAL SPECTRUM
→ effective primarily against gram (+) organisms
→ lifesaving in treatment of MRSA, MRSE, and enterococcal
infection

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

D

83
Q

to prevent emergence of vancomycin resistant organisms,
vancomycin use is restricted to:
o serious infection caused by B-lactam resistant gram (+)
organisms
o patients with gram (+) infection and allergic to B-lactams

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

D

84
Q

limited for treatment of antibiotic-associated colitis due to C. difficile or Staphylococci

A. Oral Vancomycin
B. Vancomycin
C. Vancomycin + Aminoglycoside

A

A

85
Q

used in patients with prosthetic heart valves and in patients undergoing implantation of prosthetic

A. Oral Vancomycin
B. Vancomycin
C. Vancomycin + Aminoglycoside

A

B

86
Q

used in treatment of enterococcal endocarditis

A. Oral Vancomycin
B. Vancomycin
C. Vancomycin + Aminoglycoside

A

C

87
Q

Vancomycin-resistant organisms may be treated with the ff?

A

Daptomycin

Qunipristin/Dalfopristin & Linezolid

88
Q

a cyclic lipopeptide antibiotic

A. Daptomycin
B. Qunipristin/Dalfopristin & Linezolid

A

Daptomycin

89
Q

protein synthesis inhibitors

A. Daptomycin
B. Qunipristin/Dalfopristin & Linezolid

A

C

90
Q

RESISTANCE
→ due to:
o plasmid-mediated changes in permeability to the drug
o decrease binding of vancomycin to receptor molecules

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

D

91
Q

→ mixture of polypeptides that inhibit cell wall synthesis
→ active against wide variety of gram (+) organisms
→ use is restricted to topical application (due to nephrotoxicity)

A. PENICILLIN
B. CEPHALOSPORINS
C. B-LACTAMASE INHIBITORS
D. VANCOMYCIN
E. BACITRACIN
F. DAPTOMYCIN

A

E

PHARMA (15 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions